Meet The Professors: Pancreatic Cancer Edition, 2016 - Video 13Efficacy of modified FOLFIRI versus nal-IRI and 5-FU for refractory, advanced pancreatic cancer
1:05 minutes.
TRANSCRIPTION:
DR LOVE: Didn’t you report a series at the last ASCO GI meeting on FOLFIRI in pancreatic? DR BEKAII-SAAB: Yes. And this is published now in Medical Oncology. DR LOVE: What did you see there? DR BEKAII-SAAB: So I must say that, compared to nanoliposomal irinotecan, the data was historically not as good. And the other thing is, we have seen no responses whatsoever, mostly stable diseases. Whereby if you look at the nal-IRI plus 5-FU study, there was a reported 17 % response rate in the second and third line. And then when it was reviewed centrally, it was closer to 10%, which, with 5-FU, it was 1%. So you know that there is some synergism between the two. Whether that translates into an overall survival outcome compared to FOLFIRI, that has never been tested. But our data suggests that, again, if you don’t have access to nanoliposomal irinotecan, let’s say — a lot of countries don’t have it approved — I think irinotecan is a reasonable option. |